Q-omics provides the consensus-scored CD74 profile across patient tissues and cancer cell-line models. CD74 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, CD74 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, CD74 protein abundance shows 23,633 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight SKCM, KIRC, and LSCC as cancer lineages where CD74 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CD74 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CD74 survival associations across molecular data types. CD74 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CD74 RNA expression–survival associations across cancer types. High CD74 expression shows unfavorable associations in UVM and LGG, but favorable associations in SKCM, BRCA, HNSC and UCEC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for CD74 RNA expression.
This table summarizes CD74 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CD74. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CD74 shows lower tumor expression in LUAD and LUSC and higher tumor expression in KIRC, THCA, LIHC and STAD. The KIRC box plot shows higher CD74 RNA expression in tumor versus normal tissue (log2 FC = +1.888, t-test p < 0.001).
This table shows molecular features associated with CD74 in patient tissues and cancer cell lines. In patient samples, CD74 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CD74 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
